Latest News
Certa Therapeutics’ investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases
Research presented today by University of Michigan Medical School highlights FT011’s ground-breaking treatment potential from human expression profiles in chronic kidney disease study supported by animal model data The research demonstrated that...
Uniseed invests in Tiny Bright Things (TBT), a light microscopy technology to image and measure at any scale
Melbourne, 3 November 2022 – Uniseed has led a $1.5M investment round in the Australian microscopy products company Tiny Bright Things (TBT) to transform the way researchers and manufacturers see and measure tiny or transparent objects....
Uniseed invests in University of Queensland Quantum Computing Technology company, Analog Quantum Circuits.
Brisbane, 11 October 2022 - Uniseed has committed $3M to an investment in Australian quantum technology company Analog Quantum Circuits (AQC) to fund the development of key components required for the scale up of quantum...
Uniseed investee Morse Micro, Australia’s largest semiconductor maker, today announced $140M in Series B funding
SYDNEY – Sept. 7th, 2022 – Uniseed investee Morse Micro, a fabless semiconductor company reinventing Wi-Fi for the Internet of Things (IoT), today announced $140M in Series B funding. The round was led by MegaChips Corporation, a leading ASIC and SoC services...
Uniseed investee company Occurx receives $16m cash injection to progress first-in-class therapy for inflammation and fibrosis
Australian start-up OccuRx accelerates therapy development for diseases associated with inflammation and fibrosis - the cause of 45% of all deaths globally1 Melbourne, 05 September 2022: Australian biotech start-up OccuRx today announces a $16m cash...
$1 Billion Raised by Uniseed-supported start-ups
27 July 2022 Uniseed is delighted to announce that it has reached a significant milestone, with over $1 Billion now raised by Uniseed-funded start-ups affiliated with its five partner research organisations: CSIRO, The University of Queensland, University of...
Uniseed invests in Bioscout’s Real-Time Airborne Disease Detection for Crops
20 June 2022: Uniseed-managed funds have committed $1.8M to an investment in Australian technology company BioScout alongside other investors such as Artesian Alternate Investments and Stoic VC in a $3M Seed financing round to fund process optimisation,...
ENA Respiratory Selected for the BLUE KNIGHT™ Program to Accelerate Development of Pan-Antiviral Nasal Spray
Sydney, Australia, 12th May 2022 - ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and...
UniSuper invests with Uniseed, Australia’s longest-running early-stage commercialisation fund
UniSuper, the $106 billion fund now open to all Australians, has today announced it has secured an investment relationship with Australia’s longest-established early-stage commercialisation fund manager - Uniseed 24 March 2022 - Uniseed, like UniSuper,...
First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray
-- ENA Respiratory begins influenza challenge study for fast-acting nasal spray INNA-051, designed to boost innate immunity in patients at high risk of severe complications from respiratory infections Sydney, Australia, 16 March 2022 – Uniseed...